Alkermes in the Third Quarter: A Performance Overview
Alkermes (ALKS) reported its third-quarter results on October 23. It generated net revenues of $248.7 million, a 14% YoY growth.
How’s Alkermes Positioned Financially in September?
In the second quarter, Alkermes (ALKS) reported revenues of $304.6 million—compared to $218.8 million in the second quarter of 2017.
What Does Nektar Therapeutics’ Valuation Trend Indicate?
Under its immunology program, Nektar Therapeutics (NKTR) is developing NKTR-358 in collaboration with Eli Lilly and Company (LLY).
What Analysts Think of PolarityTE and Its Peers
In June, PolarityTE stock has been given a “buy” rating by the one analyst covering it. The target price for the stock is $65.
Why Heron Therapeutics Rose 33% in Pre-Market Trading Today
Heron Therapeutics (HRTX) stock surged after the company announced it had received breakthrough designation from the FDA for its postoperative pain management drug, HTX-011.
What’s the Upside Potential of Nektar Therapeutics?
Of the 12 analysts covering Nektar Therapeutics in June 2018, 11 analysts have given the stock a “buy” or higher rating.
A Deeper Look at Alkermes’ Key Marketed Products
Alkermes’ (ALKS) Aristada is an intramuscular injectable suspension for the treatment of schizophrenia.
Analysts’ Ratings for Alkermes and Its Peers in February 2018
Of the 12 analysts covering Alkermes (ALKS) in February, five analysts gave ALKS a “buy” rating. Seven analysts gave it a “hold” rating.
A Look at Alkermes’ Diabetes Product Portfolio
According to Alkermes, ~26.0 million people in the US and 382.0 million people globally are affected by diabetes.
An Insight into Alkermes’ R&D Pipeline
Alkermes’ ALKS3831 is an investigational oral medicine is targeted for the treatment of schizophrenia.
Exploring Alkermes’ Financial Performance in Fiscal 2017
Alkermes (ALKS) generated total revenues of $903.0 million in fiscal 2017 compared with $745.6 million in fiscal 2016.
Analyst Ratings for Vanda Pharmaceuticals and Peers in February
Of the six analysts covering Vanda Pharmaceuticals in February 2018, two of them have given the stock a “strong buy” rating.
Analyst Recommendations for Nektar Therapeutics in November 2017
In 3Q17, Nektar Therapeutics (NKTR) reported revenues of $152.9 million, a YoY rise of 320.7%. The sudden spurt is mainly due to the upfront payment of $150 million from Eli Lilly.
This Sector Has Hurt the Fidelity Growth Company Fund so Far in 2016
The Fidelity Growth Company Fund (FDGRX) places ninth in the YTD period among the group of 12 funds we’ve chosen for this review.
What’s the Sector Composition of the FNGAX?
The Franklin International Growth Fund invests “in the equity securities of mid- and large-capitalization companies outside the U.S. with long-term growth potential.”
What’s Been Beating down the Fidelity Growth Company Fund in 2016?
FDGRX has declined by 0.7% YTD (year-to-date) in 2016. This decline has led to the fund being among the below-average funds in our group of 12.
The Franklin International Growth Fund’s Portfolio Moves in YTD 2016
In the past 12 months until May 2016, Franklin International Growth Fund (FNGAX) has witnessed increased exposure to discretionary and healthcare stocks.
How Does XBI Compare to Its 100-Day Moving Average?
The SPDR S&P Biotech ETF (XBI) rose marginally by 0.1% on April 20, 2016. Within XBI, Kite Pharma (KITE) closed at $48.98 on the day.
XBI News as of March 16: Mid-Caps Under Pressure
Given selling pressures, XBI’s 18 mid-cap stocks went down marginally on average, losing 0.4% on March 16. Eight stocks advanced while ten stocks declined.
What You Should Know about the Franklin International Growth Fund
The Franklin International Growth Fund – Class A (FNGAX) was incepted in June 2008 and has an expense ratio of 1.4%.
How Has the Fidelity Growth Company Fund Performed in 2016?
The Fidelity Growth Company Fund (FDGRX) was among the top five largest funds in this peer group, managing assets worth $36.0 billion as of January 2016.
Alexion Continues to Rise on FDA’s Approval of Kanuma
Alexion Pharmaceuticals (ALXN) gained 2.5% on December 10, 2015. The stock went up after the FDA (Food and Drug Administration) approved its drug, Kanuma.
How Are IBB’s American Depositary Receipts Performing?
The ADRs of the iShares Nasdaq Biotechnology ETF (IBB) had negative returns of 1% for the week ended December 4, 2015. IBB provides good exposure to international biotech stocks.
Europe Approved Biogen’s Elocta, Topped XBI’s Large-Cap Stocks
Biogen rose 1% on November 25. It closed at $292.30. It was trading 5.7% below the 100-day moving average price of $309.85. It passed the 20-day moving average.
Amgen Rises by 2% as XBI’s Large-Cap Stocks Rally
Amgen closed at $157.60 and was trading above its 50- and 100-day moving averages. The stock also witnessed a rise in trading volumes.
AbbVie, Lead Performer of the Pharmaceutical Subgroup
AbbVie (ABBV) rose 18.3% for the week ended October 30, 2015, and closed at $59.55. The stock went up on good 3Q15 earnings.
Alkermes’s Multi-Pronged Strategy for Its Aristada Launch
Alkermes plans a multi-pronged strategy for Aristada’s successful launch, which will involve flexible usage, effective pricing, and additional research.
Alkermes’s Aristada and Its FDA Approval for Schizophrenia
Aristada was approved by the FDA and is projected to account for 10% to 30% of the LAI atypical antipsychotic market for schizophrenia patients in the US.
Alnylam Up 2.0% on Phase 1 Initiation of OLE Study with ALT-AT3
Alnylam Pharmaceuticals (ALNY) rose 2.0% on news that it has initiated a Phase I open-label extension (or OLE) study with ALN-AT3 for the treatment of hemophilia and rare bleeding disorders.
In 2014, prescription pharmaceuticals generated revenue of $542.84 million, and consumer health generated revenue of $50.23 million— 91.5% and 8.5% of total revenue, respectively.
Top Ten of XBI Outperform by Market Cap
The average return of the top ten IBB stocks was -4.73%, while the average return of top ten XBI stocks was -3.89% for the week ended September 4, 2015.
Healthcare and Pharmaceuticals Prevail in Stable Market Conditions
The healthcare sector and the pharmaceutical sector underperformed IBB, but outperformed the broader index SPY for the week ending July 31, 2015.
What Led Large-Cap Stocks to Outperform Mid and Small Caps?
Within the iShares Nasdaq Biotechnology ETF (IBB), for the week ending July 31, 2015, the top ten large-cap stocks had a weight of 56.59% of IBB’s portfolio.
Pharma Stocks Show a Positive Trend
The upward trend in the pharmaceutical sector for the week ending July 17, 2015, was not caused by the oversold or overbought condition.